Status:
COMPLETED
A Study of MK-1084 With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to midazolam and dig...
Eligibility Criteria
Inclusion
- The key inclusion criteria include but are not limited to the following:
- Is medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vitals signs, and electrocardiograms (ECGs)
- Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive
Exclusion
- The key exclusion criteria include but are not limited to the following:
- Has a medical history that may confound the results of the study or poses an additional risk to the participant in the study
- Has a history or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds
Key Trial Info
Start Date :
September 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 28 2024
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06575933
Start Date
September 3 2024
End Date
October 28 2024
Last Update
November 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion ( Site 0001)
Tempe, Arizona, United States, 85283